Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftriaxone
Drug ID BADD_D00405
Description Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.[A215582]
Indications and Usage Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms.[L15082] Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.[A215582]
Marketing Status approved
ATC Code J01DD04
DrugBank ID DB01212
KEGG ID D07659
MeSH ID D002443
PubChem ID 5479530
TTD Drug ID D07ACT
NDC Product Code 72572-061; 25021-105; 25021-107; 44567-700; 63323-346; 0143-9859; 66794-213; 71205-593; 72572-062; 66794-215; 70594-098; 44567-701; 66794-211; 70518-3355; 25021-106; 0143-9856; 44567-702; 66794-214; 70594-094; 70594-097; 0264-3155; 66794-212; 44567-703; 0264-3153; 70594-095; 70594-096; 0143-9678; 0143-9857; 0143-9858
UNII 75J73V1629
Synonyms Ceftriaxone | Ceftriaxon | Cefatriaxone | Ceftriaxone, Disodium Salt, Hemiheptahydrate | Ceftrex | Ceftriaxon Curamed | Ceftriaxon Hexal | Ceftriaxona Andreu | Ceftriaxona LDP Torlan | Ceftriaxone Irex | Ceftriaxone Sodium | Ceftriaxone Sodium, Anhydrous | Anhydrous Ceftriaxone Sodium | Lendacin | Longacef | Longaceph | Ro13-9904 | Ro13 9904 | Ro139904 | Ro-13-9904 | Ro 13-9904 | Ro 13 9904 | Ro 139904 | Rocephin | Rocefalin | Rocephine | Rocefin | Tacex | Terbac | Ceftriaxone, Disodium Salt | Benaxona | Cefaxona
Chemical Information
Molecular Formula C18H18N8O7S3
CAS Registry Number 73384-59-5
SMILES CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.011141%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.033424%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drooling17.02.05.0050.004457%Not Available
Drug eruption08.01.06.015; 23.03.05.001; 10.01.01.0050.017826%Not Available
Drug hypersensitivity10.01.01.0010.332458%Not Available
Drug interaction08.06.03.0010.044565%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.0060.020946%
Dyspnoea02.11.05.003; 22.02.01.0040.253132%
Dystonia17.01.03.0010.006685%Not Available
Ear swelling04.03.01.014--Not Available
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.0010.006685%Not Available
Eczema23.03.04.0060.006685%
Encephalopathy17.13.02.0010.028968%
Enteritis07.08.03.0020.004457%
Enterocolitis07.08.03.003--
Eosinophilia01.02.04.0010.092251%
Eosinophilic pneumonia22.01.01.004; 01.02.04.0030.006685%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.026739%
Erythema23.03.06.0010.214360%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.041000%
Eye swelling06.08.03.0030.006685%Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.0040.019609%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.033424%
Febrile neutropenia08.05.02.004; 01.02.03.002--
Feeling abnormal08.01.09.014--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 16 Pages